New Delhi, Mar 11 (KNN) The Indian government has invited expressions of interest (EoI) for research and development (R&D) projects aimed at developing innovative medical technologies, including drugs and medical devices, to combat communicable and non-communicable diseases.
The initiative, spearheaded by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers, falls under the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme.
The PRIP scheme, with a financial outlay of Rs 5,000 crore, is structured into two components. The first, amounting to Rs 700 crore, is dedicated to establishing Centres of Excellence (CoEs) at seven National Institutes of Pharmaceutical Education and Research (NIPERs).
These centers will focus on drug discovery for conditions such as hypertension, lung disease, cancer, diabetes, and rare diseases.
The CoEs will also facilitate research in anti-viral and anti-bacterial drugs, medical devices, bulk drugs, and biological therapeutics.
The second component, with an allocation of Rs 4,250 crore, aims to boost private sector investment in R&D.
The government will provide financial support to companies engaged in priority research areas, including drug discovery, medical devices, stem cell therapy, and treatment for drug-resistant infections.
Large companies can avail funding up to Rs 125 crore, while startups can secure up to Rs 1 crore over five years, contingent on milestone achievements.
Amit Agrawal, Secretary of the Department of Pharmaceuticals, emphasized the importance of industry participation, stating, “Funding will be directed towards industry, but collaborations with academia are encouraged.
We will evaluate proposals based on their public health impact and feasibility.” The final date for EoI submissions is April 7, with the application process beginning in late April or early May.
Despite India’s dominance in generic drug manufacturing, its annual pharma R&D investment remains significantly lower than global competitors. Experts stress the need for enhanced innovation to secure India’s future as a leader in pharmaceutical advancements.
(KNN Bureau)
